FDA Brief

Warning letters Food

FDA warning letter to

A&Z Pharmaceutical, Inc.

LowIssued Jun 1, 2023Posted Jun 13, 2023Division of Human and Animal Food Operations East I

A&Z Pharmaceutical marketed a kids’ calcium supplement with disease claims, making it an unapproved and illegally labeled drug.

What happened

In April 2023, FDA reviewed the company’s website and Facebook pages and found it takes orders for Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor. FDA cited claims that the product can prevent or treat diseases including osteoporosis, gum disease, depression, hypocalcemia, colon cancer, high blood pressure, osteopenia, hair loss, rickets, and Covid-19. FDA said these claims make the product an unapproved new drug (a product needing FDA approval for those uses) and misbranded (lacking adequate directions for safe lay use).

What FDA found

  1. Website and Facebook posts claim the children’s calcium product prevents or treats diseases such as osteoporosis, gum disease, depression, hypocalcemia, colon cancer, high blood pressure, osteopenia, hair loss, rickets, and Covid-19.

    Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. Because the product is not generally recognized as safe and effective for those disease uses, FDA calls it a new drug, meaning it lacks FDA approval for those uses.

    Section 201(p) of the Act [21 U.S.C. 321(p)]
  3. The company offers the product for interstate commerce without FDA approval.

    Sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]
  4. The product lacks adequate directions for use for its intended disease uses, so FDA calls it misbranded.

    Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]
  5. The product is misbranded and its introduction into interstate commerce violates the Act.

    Section 301(a) of the Act [21 U.S.C. 331(a)]

What FDA wants

FDA asks the company to reply in writing within 15 working days of receiving the letter, describing specific steps taken to correct the violations and prevent recurrence, with documentation. If corrective actions cannot be completed in that time, the company must explain the delay and state when it will finish.

Who should pay attention

  • dietary supplement brands that make disease-related claims online
  • marketers using social media for supplement claims
  • companies selling children's supplements with health claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk